

Learning Objectives

At the completion of this activity, the participant will be able to:

1. Review recent oncology guideline updates.
2. Evaluate the impact of newly approved drugs in the treatment of patients with solid tumors.
3. Describe new indications for drugs used in patients with solid tumors.
4. Incorporate updates into clinical practice and describe how they apply to BCOP testing.
5. Identify FDA-approvals of novel and existing therapies in the treatment of acute leukemia, chronic leukemia, lymphoma, and myeloma.
6. Evaluate clinical data supporting recent FDA-approvals in hematologic malignancies.
7. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with hematologic malignancies as it relates to newly approved therapies.

Conflict of Interests

No faculty, reviewer, or program planner for this activity has any relevant conflicts of interest to disclose.